GlassScriptPhysician profile
Brian Adams
NPI 1144492943
$14,133.94
in general payments reported to CMS, 2019-2025
23 companies · $567 in 2025
The $567 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,642 · 2020: $1,443 · 2021: $680 · 2022: $1,456 · 2023: $3,214 · 2024: $4,132 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,969 · Food and Beverage: $3,944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,968.99 |
| Food and Beverage | $3,944.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $3,111.44 | 2020-2025 | Indigo System, Penumbra System, Ruby Coil |
| W. L. Gore & Associates, INC. | $3,018.23 | 2019-2025 | Gore Tag Thoracic Endoprosthesis, Gore Tag Thoracic Branch Endoprosthesis, Product In Development |
| Silk Road Medical, INC. | $2,288.52 | 2019-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Inari Medical, INC. | $2,262.66 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Centinel Spine, LLC | $1,172.34 | 2020 | |
| Bolton Medical INC | $742.19 | 2019-2025 | Treo Abdominal Stent-Graft System, Relay Thoracic Stent-Graft With Plus Delivery System |
| Medtronic, INC. | $247.15 | 2021-2024 | Abre, Venaseal |
| Cook Medical LLC | $220.79 | 2020-2025 | Zenith Alpha, Zenith, Lunderquist |
| Shockwave Medical, INC | $218.82 | 2023-2024 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave M5+, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave E8 Peripher, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $216.06 | 2019-2025 | General - Vascular Intervention, Enroute Transcarotid Neuroprotection System |
| Janssen Pharmaceuticals, INC | $142.06 | 2019-2024 | Xarelto |
| Organogenesis INC. | $117.66 | 2020 | |
| Bard Peripheral Vascular, INC. | $83.51 | 2021-2023 | Venclose Maven Catheter, Venovo |
| Cvrx, INC. | $80.05 | 2023 | Barostim Neo System |
| Stryker Corporation | $45.36 | 2025 | Limflow System |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dentsply Sirona INC | $43.11 | 2023 | Suresmile |
| Abbott Laboratories | $36.79 | 2025 | Esprit |
| Becton, Dickinson and Company | $17.64 | 2024 | Crosser Iq |
| Surmodics, INC. | $14.82 | 2021 | |
| Lemaitre Vascular, INC. | $14.66 | 2024 | Artegraft Vascular Graft |
| Janssen Scientific Affairs, LLC | $14.30 | 2022 | |
| Philips North America LLC | $14.19 | 2025 | Labosys |
| Terumo Medical Corporation | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.